tradingkey.logo
tradingkey.logo
Search

BioArctic Says Rolling sBLA Initiated To The U.S. FDA For Leqembi As Subcutaneous Starting Dose For Treatment Of Early Alzheimer's Disease Under Fast Track Status

ReutersSep 2, 2025 11:33 PM
facebooktwitterlinkedin

- BioArctic AB BIOAb.ST:

  • ROLLING SBLA INITIATED TO THE U.S. FDA FOR LEQEMBI® IQLIK™ (LECANEMAB-IRMB) AS A SUBCUTANEOUS STARTING DOSE FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE UNDER FAST TRACK STATUS

Further company coverage: [BIOAb.ST]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI